Genetically modified antigen-presenting cells (APC) represent an attractive strategy for in vitro immunomodulation. In the human system, APC expressing HLA-A1 and a membrane-bound form of CD95L (m-CD95L) were used for selective depletion of HLA-A1-specific T cells. In short-term assays, m-CD95L-expressing APC-induced apoptosis in activated T cells and the constitutive presence of m-CD95L and HLA-A1 expressing APC in long-term T cell cultures prevented the expansion of CD4 þ and CD8 þ HLA-A1-specifc T cells and the development of HLA-A1-specific cytotoxicity. However, immunity towards third party, viral and bacterial antigens was maintained and T cells spared from depletion could be induced to develop cytotoxicity towards unrelated antigens. Interestingly, inhibition of HLA-A1-specific T cell response absolutely requires the coexpression of m-CD95L and HLA-A1 antigen on the same APC. Thus, m-CD95L expressing APC might be used in clinical settings to obtain tolerance induction in allogeneic transplantation systems or autoimmune diseases. Apoptosis mediated by the CD95 system plays a pivotal regulatory role in the maintenance of immune homeostasis. Deficiency in CD95 or CD95L expression in T cells mediates lymphoproliferative disorders due to the lack of apoptosis induction. 1 Paradoxically, several molecules of the CD95 signaling pathway are also required for T cell activation and proliferation.
Apoptosis mediated by the CD95 system plays a pivotal regulatory role in the maintenance of immune homeostasis. Deficiency in CD95 or CD95L expression in T cells mediates lymphoproliferative disorders due to the lack of apoptosis induction. 1 Paradoxically, several molecules of the CD95 signaling pathway are also required for T cell activation and proliferation. 2 In addition to T cells, live and death of antigenpresenting cells, which initiate T cell responses has to be tightly controlled to avoid the establishment of autoimmunity. 3 Activation-induced cell death (AICD) represents an apoptosis mechanism mediated via the interaction of CD95 with its ligand CD95L, to mediate T cell death and initiate the termination of an immune response to maintain tolerance to self antigens and to prevent autoimmunity. 4 Owing to the constitutive expression of CD95L in immune privileged organs such as testis or eye, 5, 6 CD95L was considered as an immunoprotective agent able to counterattack activated T cells in vivo. However, the role of CD95L in transplantation tolerance is still controversial. While allogeneic pancreatic islands transplanted together with syngeneic CD95L expressing myoblasts were tolerated, 7 allogeneic CD95L expressing pancreatic b cells were rejected due to increased neutrophil infiltration. 8 Lack of immunogenicity of tumors and resistance towards T cell attacks were also correlated with the expression of CD95L on tumor tissues. Such tumors were shown to kill CD95-positive cells in vitro. 9 However, transfection of CD95L into murine tumor cells did not enhance tumor growth, but instead induced accelerated tumor rejection by neutrophils in vivo. [10] [11] [12] Systemic immunomodulation by CD95L was successfully achieved by antigen-presenting cells modified to express CD95L. 13 In mice antigen-specific elimination of activated T cells by engagement of CD95L on APC and CD95 on the activated T cells has been demonstrated in several models. 14, 15 This approach benefits from the high specificity since only T cells responding to the antigen expressed on the APC are deleted by CD95/CD95L interaction while the remaining T cells are still responsive to unrelated antigens. However, successful elimination of antigen-specific T cells via the CD95 system depends on the CD95-sensitivity of T cells. As human naïve T cells are resistant to CD95-mediated apoptosis and acquire CD95-sensitivity only after activation, 16 interaction with CD95L might delete activated T cells in an allospecificimmune response in vitro while leaving non-activated naïve T cells untouched.
Human CD95L exists in a membrane-bound (m-CD95L) and soluble (s-CD95L) form, which is generated from the membrane-bound form through cleavage at the cell surface by metalloproteinases. 17 While membrane-bound CD95L efficiently mediates apoptosis in CD95 expressing cells by formation of trimers or higher molecular structures, s-CD95L can have pro-or antiapoptotic functions depending on the microenvironment. 17, 18 s-CD95L is proapoptotic if oligomers are formed with the extracellular matrix but antiapoptotic by competing with the m-CD95L for binding to CD95 in the absence of oligomer formation. 18 Cells transfected with m-CD95L have been shown to efficiently induce cell death in T cell lines and lymphocytes. 19, 20 Thus, m-CD95L-expressing APC might be used in vitro to selectively deplete antigen-specific T cells in solid organ transplantations to prevent graft rejection or to remove host-reactive T cells from allogeneic bone marrow transplants to minimize the risk of graft-versus-host disease.
To evaluate such a counterattack system for selective depletion of human T cells in vitro, we analyzed the modulation of an allospecific immune response in the presence of m-CD95L-expressing APC. Long-term T cell cultures continuously stimulated with the alloantigen were used as a system to monitor the activation of antigen-specific T cells over an extended time period. Weekly stimulation of HLA-A1 À T cells with APC coexpressing HLA-A1 and m-CD95L induced the selective depletion of HLA-A1-specific T cells while immunogenicity and cytotoxicity towards unrelated antigens were maintained.
Results m-CD95L expressed on APC efficiently kills T cells. To obtain APC expressing membrane-bound CD95L (m-CD95L) we cultured the HLA-A1 expressing LCL C1R.A1 in the presence of a-CD95mAb (up to 5mg/ml) for 8 weeks and subsequently performed limiting dilution to obtain CD95 negative clones (C1R.A1.CD95 À ). C1R.A1.CD95
À cells were transfected with the cDNA coding for m-CD95L, which is expressed on the cell surface due to a mutation in the metalloproteinase cleavage site 17 together with the puromycinresistance selection vector or the selection vector alone. m-CD95L expressing single cell clones were obtained from bulk cultures by limiting dilution (C1R.A1.CD95L) and cells expressing the puromycin-resistant vector alone (C1R.A1.puro) were used as a control. Surface expression of CD95, CD95L, HLA-A1 and of costimulatory molecules CD80 and CD86 on the different cell lines is shown in Figure 1a . To confirm that m-CD95L induces apoptosis, we cocultured C1R.A1.CD95L or C1R.A1.puro together with the human T cell line Jurkat (CD3 þ , CD95 þ ) for 3.5 h and analyzed cell death in the CD3 þ population. While Jurkat cells cocultured with C1R.A1.puro revealed no signs of apoptosis, we detected 81% Annexin-V þ Jurkat cells in the presence of C1R.A1.CD95L. Apoptosis induction by m-CD95L was extremely efficient compared to the agonistic anti-CD95 antibody (APO-1), which induced only 24% Annexin-Vpositivity at this early time point. Jurkat-8 À/À cells, deficient for caspase-8 expression and insensitive for apoptosis induction via the CD95 pathway were resistant towards C1R.A1.CD95L and APO-1 treatment (Figure 1b) . C1R.A1.CD95L cells also lysed activated T cells such as Jurkat cells, PHA-activated human T cells or HLA-A1-specific CTL in a standard chromium release assay. While lysis of Jurkat cells started already after 4 h, CD4
þ and CD8 þ PHA blasts and HLA-A1-specific CTL or total HLA-A1-specific CTL þ and CD8 þ T cells stimulated by C1R.A1.CD95L did not respond to HLA-A1-expressing cells but were activated by third-party alloantigens while C1R.A1.puro stimulated T cells proliferated in response to HLA-A1.
T cells cultured in the presence of m-CD95L retain antiviral and antibacterial immunity. HLA-A2 and HLA-35 molecules, expressed on the LCL C1R.A1 in such a low amount that they are only detectable by HLA-A2-or -B35-specific CTL but remain serologically undetectable, 21 might present Epstein-Barr-virus (EBV)-specific T cell epitopes. 22 To further prove antigen-specificity of the depletion process, we analyzed whether autologous EBV-specific T cell responses were retained. After depletion of HLA-A1-specific T cells by four rounds of stimulation with C1R.A1.CD95L, remaining T cells were stimulated in a mixed lymphocyte reaction (MLR) with the autologous EBV line and C1R.A1 cells (Figure 4a m-CD95L expressing APC prevent the activation of HLA-A1-specific CTL. As stimulation with HLA-A1 expressing C1R.A1.CD95L cells prevent the activation of CD8 þ T cells (see Figure 2) , we examined whether the presence of m-CD95L expressing APC could prevent the development of HLA-A1-specific CTL. Standard chromium release assays using T cells from C1R.A1.puro or C1R.A1.CD95L-stimulated cultures after different rounds of stimulation were used to test cytotoxicity towards the HLA-A1 expressing mouse mastocytoma cell line P1.A1 23 and the parental line P1.HTR (P1) (Figure 5a ). C1R.A1.puro stimulated T cells started to exhibit HLA-A1-specific cytotoxicity after three rounds of stimulation and the lytic capacity of T cells increased with further stimulation. The presence of m-CD95L on APC, however, prevented the activation of HLA-A1-specific CTL. To confirm that the lack of HLA-A1-specific cytotoxicity in the m-CD95L-stimulated cultures was not due to the decreased number of CD8 þ T cells compared to cultures stimulated by C1R.A1.puro (as shown in Figure 2 ), we isolated CD4 þ and CD8 þ T cells from both cultures after the fifth round of stimulation. While CD4 þ T cells in both systems exhibited no cytotoxicity, only CD8 þ T cells stimulated by C1R.A1.puro developed HLA-A1 reactivity (Figure 5b ). Most probably, HLA-A1-specific CTL recognized HLA-A1 determinants independent of the peptide presented, since the murine TAP-2 deficient RMA-S cells expressing HLA-A1 were also lysed, although less efficiently (Figure 5c ). RMA-S.A1 expressed only class I molecules on the cell surface, which have been loaded with peptides in an TAP1/2-independent manner, thus completely differing in their peptide repertoire from TAP1/2 expressing P1.A1 cells. 24 CTL established in the presence of m-CD95L retain their cytotoxic capacity. As the presence of m-CD95L and HLA-A1 on APC inhibited the development of CD8 þ HLA-A1-specific CTL (Figure 5b) , we examined whether nondepleted T cells still expressed mediators of T cell cytotoxicity. After five rounds of stimulation, CD4
þ and CD8 þ T cells were isolated from cultures either activated by C1R.A1.puro or C1R.A1.CD95L and expression of perforin, granzyme B, CD95L and TRAIL was determined (Figure 6a ). Granzyme B expression was present in the C1R.A1.CD95L stimulated CD8 þ T cell cultures but more pronounced in the CD8 À T cells were weekly stimulated with C1R.A1.puro or C1R.A1.CD95L cells and cytotoxic capacity was measured after 4 or 5 rounds of stimulation on HLA-A1 expressing target cells (P1.A1) and the HLA-A1 negative parental line (P1) in a standard chromium release assay (a). After five rounds of stimulation with C1R.A1.puro or C1R.A1.CD95L CD4 þ and CD8 þ T cells were isolated and the cytotoxic capacity of the single subsets was tested on HLA-A1 expressing targets (b). HLA-A1-specific CTL after the fourth stimulation were incubated with P1, P1.A1, RMA-S and RMA-S.A1 cells in a standard chromium release assay and cytotoxicity was analyzed after 4 h (c). Data are representative for four independent experiments with similar results m-CD95L-mediated antigen-specific T cell depletion G Strauss et al EBV-cytotoxicity was detectable but only slightly increased compared to unspecific background lysis towards P1 (Figure 6d ) but developed after restimulation with the autologous EBV cell line (Figure 6e ). In summary, these results show that m-CD95L expressing APC specifically inhibited the activation of HLA-A1-specific CTL but did not impair their non-HLA-A1-specific cytotoxic potential.
Coexpression of m-CD95L and HLA-A1 alloantigen on the same APC is required to inhibit allogen-specific T cell responses. Next, we studied whether m-CD95L-mediated inhibition of allogen-specific T cell activation requires coexpressing of HLA-A1 and m-CD95L on the same APC. Therefore, we transfected m-CD95L into the 
Discussion

CD95L expressed on T cells mediates a dual function: effective destruction of CD95
þ target cells and induction of suicide or fratricide of activated T cells at the termination phase of an immune response. 4 As CD95L expression turns T cells into cytotoxic killer cells and simultaneously renders them susceptible for CD95-induced cell death, we questioned whether APC expressing CD95L could mediate antigenspecific T cell depletion. The HLA-A1 expressing LCL C1R.A1.CD95
À was transfected with m-CD95L, which leads to stable surface expression of CD95L. m-CD95L-expressing APC efficiently induced apoptosis in CD95 expressing T cells. The presence of m-CD95L in T cell stimulation cultures prevented T cell expansion, HLA-A1-specific T cell responses and the activation of HLA-A1-specific cytotoxic T cells.
Although APC are the most potent inducers of T cell activation, they may also be suitable for antigen-specific tolerance induction. In murine systems antigen-specific T cell deletion and tolerance induction in vitro and in vivo was achieved by CD95L-transfected APC. 14, 15 Also in the human system mature but not immature human DC retrovirally transduced with murine CD95L induced apoptosis induction in CD95-expressing T cells in vitro. 25 However, to our knowledge, efficient alloantigen-specific depletion by APC expressing m-CD95L without impairment of immunity towards environmental antigens is shown here for the first time in the human system. Reports by Dulat et al. showed that CD95L transfected 293 human embryonic kidney cells induced modulation of an allo-immune response but failed to preserve reactivity of nondeleted T cell towards third-party antigens. 26 Most likely, T cells stimulated by 293 cells are anergized, since 293 cells do not express costimulatory molecules needed for T cell activation.
While m-CD95L expressing APC efficiently induced selective T cell depletion, the role of CD95L expressed on tumors to kill tumor infiltrating lymphocytes (counterattack) or on transplanted tissues to establish immunopriviliged sites is still controversial.
27 CD95L-expressing tumor cells have been reported to kill tumor-infiltrating lymphocytes, 28, 29 while other studies demonstrated that CD95L expression on tumors induced tumor rejection by inflammation in vivo. 10, 30 The controversial data indicate a discrepancy between the in vitro and in vivo action of CD95L. Although CD95L-expressing cells efficiently mediate cell death of CD95-sensitive T cells in vitro, the same cells are apparently not protected from rejection in vivo. [10] [11] [12] As our model is operative under standardized in vitro culture conditions, T cell depletion is independent of environmental influences such as local cytokine pattern, vascularization and accessibility to cellular infiltration. The efficiency of our system might further depend on the fact that CD95L is used in a membrane-bound form. Noncleavable, membrane-bound CD95L was reported to induce death of CD95-expressing targets more efficiently than the soluble form. 17, 31 We observed that ex vivo isolated CD95 þ T cells from peripheral blood were killed by m-CD95L expressing APC (depending on the donor and the percentage of CD95 þ T cells B20-50% specific apoptosis) while CD95-sensitivity significantly increased during T cell activation (B80% specific apoptosis) (data not shown). However, the mechanism by which m-CD95L expressing APC induce allogen-specific T cell depletion is not clear. We speculate that m-CD95L expressing APC induce activation of the appropriate, naive T cells followed by upregulation of CD95 and subsequent elimination of the T cell by CD95/CD95L interaction. However, we cannot exclude that the simultaneous triggering of the TCR and the CD95 receptor inhibits T cell activation and proliferation and induces anergy. Additionally, analysis of the À PBL were stimulated with C1R.A1.puro or C1R.A1.CD95L at an effector:stimulator ratio of 10 : 1 or with a mixture of C1R.CD95L þ C1R.A1.puro at an effector:stimulator ratio of 10 : 1 : 1 (PBL:C1R.CD95L:C1R.A1.puro) and absolute T cell numbers and distribution of T cell subsets were determined after each round of stimulation (c). HLA-A1-specific cytotoxicity of T cells stimulated for four times by C1R.A1.puro (d), C1R.A1.CD95L (e) or a mixture of C1R.CD95L and C1R.A1.puro (f) was tested on HLA-A1 expressing targets (P1.A1) and the HLA-A1 negative P1 cell line. Experiments were carried out with PBL from three different donors m-CD95L-mediated antigen-specific T cell depletion G Strauss et al immunological synapse would further clarify the mechanism of m-CD95L-mediated T cell depletion. As only 5-10% of the T cells are HLA-A1 specific at the beginning of the stimulation process and we are not able to distinguish those cells from the rest of the T cell population such analysis cannot be done in our system. CD95 signaling and caspsase activation is not only linked to apoptosis induction but also to T cell activation and proliferation. 2 Along this line several reports indicated that TCR triggering protects from CD95-mediated apoptosis. [32] [33] [34] In the murine system, naïve T cells were reported to die after TCR and CD95 ligation while memory T cells were costimulated and induced to proliferate. 35 However, all systems have in common that stimulation was achieved by monoclonal antibodies instead of APC coexpressing antigen, costimulatory molecules and CD95L on the cell surface. Even if CD95L-expressing DC were used, apoptosis induction was always tested on unspecifically activated T cells for example by CD3/ CD28 activation and never on the corresponding antigenspecific T cell. 25, 36 Our results, however, clearly indicate that inhibition of T cell responses by m-CD95L cannot be prevented by TCR/antigen or CD28/B7 interaction at least if all stimuli are provided by the same APC. In accordance with this finding, elimination of antigen-specific T cells was only achieved when CD95L and antigen were coexpressed on the same APC but not if both signals were delivered via separate APC.
As m-CD95L-expressing APC efficiently deplete the corresponding antigen-specific human T cells, they provide an attractive system for elimination of host-reactive T cells in transplantation settings or autoimmune diseases in vitro. In vivo use of m-CD95L expressing APC is not suitable since we can not predict the toxic effect of m-CD95L expressing cells on CD95-expressing tissues. Although in several mouse models CD95L-expressing APC are successfully applied to eliminate antigen-specific T cells, recent reports exhibit limited success of killer dendritic cells in preventing graft rejection 37 and observed the development of pulmonary vasculitis 38 after in vivo injection.
LCL used as APC are highly efficient in activation of T cells 39 and are available in unlimited numbers. However, death ligand expressing LCL might abrogate T cell responses to minor antigens including tumor antigens restricted to the hematopoetic system in situations when antitumor responses are required for therapy. As we preserve an EBV-specific antigen-response after T cell depletion, we speculate that tumor antigens restricted to the leukemic clone and presented in the context of self-HLA might theoretically be maintained. As the establishment of LCL and transfection with m-CD95L requires time-consuming cell culture work for each individual patient, it will be worthwhile to test alternative strategies such as liposomes or microbeads coated with HLA/peptide ligands and m-CD95L.
In conclusion, the present data provide strong evidence that an alloantigen-specific immune response can be abolished by m-CD95L expressing APC without affecting reactivity towards third-party antigens. This approach might support the concept to use m-CD95L expressing APC as immunomodulators to achieve antigen-specific tolerance in transplantation settings and autoimmune diseases.
Materials and Methods Plasmids and transfection. A CD95
À variant of the lymphoblastoid cell line (LCL) C1R.A1 23 termed C1R.A1.CD95 À was electroporated (220 V, 950 mF) with plasmid pBOSHFLD4 coding for human m-CD95L, which carries a deletion at the metalloproteinase cleavage site 17 and the selection vector pSV40-puro (generously provided by B. Baumann, Ulm, Germany) (C1R.A1.CD95L) or with pSV40-puro alone (C1R.A1.puro). Selection was carried out in 0.6 mg/ml puromycin (CLONTECH Laboratories, Heidelberg, Germany) containing medium. Single cell clones were obtained from bulk cultures by limiting dilution and tested for m-CD95L-expression by flow cytometry.
Cell lines. All cell lines were grown in RPMI 1640 medium (GIBCO-BRL, Paisley, UK) supplemented with 10% heat-inactivated FCS (BioWhittacker, Verviers, Belgium), 2 mM L-glutamine and 1 mM sodium pyruvate at 371C in a humidified atmosphere containing 7.5% CO 2 .
Generation of HLA-A1-specific T cells and PHA blasts. HLA-A1-specific T cells were established as previously described. 40 In brief, one half of PBMC derived from healthy HLA-A1
À donors was stimulated with mitomycin Ctreated C1R.A1.puro cells, while the other half was stimulated with mitomycin Ctreated C1R.A1.CD95L cells and human rIL-2 (Biochrom KG) (30 U/ml) ( ¼ first stimulation). After 1 week viable cells were separated and T cells, which were previously activated by C1R.A1.puro were stimulated a second time with C1R.A1.puro while T cells originally activated by C1R.A1.CD95L were restimulated by C1R.A1.CD95L ( ¼ second stimulation). Restimulation was carried out weekly at a T cell: stimulator rate of 10 : 1 in medium containing 30 U/ ml of rIL-2. To obtain PHA blasts PBMC were stimulated with 2.5 mg/ml PHA-P (Sigma, Taufkirchen, Germany) and rIL-2 (50 U/ml). After 24 h PHA was washed away and cells were cultured for 5 days in medium containing rIL-2 (50 U/ml).
Isolation of T cell subsets. To obtain CD4
þ and CD8 þ T cells, CTL or PHA-blasts were separated by the CD4 positive and CD8 positive isolation kit (Dynal, Hamburg, Germany). Purity of the populations ranged between 97 and 100%.
Generation of EBV-transformed B-cell lines. PBMC/2.5 ml medium (1 Â 10 7 ) were incubated with 2.5 ml supernatant from the B95-8 EBV producer cell line at 371C. After 2 h, 5 ml medium and 1 mg/ml Cyclosporine A (Sigma) was added. At 3 weeks after infection, cultures were expanded.
Measurement of apoptosis induction. Induction of apoptosis was determined by Annexin-V-FITC staining (Annexin-V-FITC kit, Bender Med Systems, Vienna, Austria) on a FACScan Cytometer (BD Biosciences, Heidelberg, Germany).
Chromium release assays. Target cells (2 Â 10 6 ) were labeled with 100 mC i Na 51 CrO 4 (Amersham-Buchler, Braunschweig, Germany) for 1 h. Increasing numbers of effector cells were titrated to 5 Â 10 3 target cells and incubated for 4 or 12 h at 371C. 50 ml of supernatant was assayed for 51 Cr-release in a Top CountNXTt counter (Perkin Elmer, Rodgau-Jügesheim, Germany). Maximum release was determined by incubation of target cells in 100 ml 10% SDS and spontaneous release was determined by addition of medium. The percentage of specific release was calculated as % specific release ¼ (experimental releasespontaneous release)/(maximum release-spontaneous release) Â 100. Assays were set up in triplicates and performed at day 6 after T cell stimulation. À PBMC for 6 days in the presence of PPD (1 mg/ml, Chiron-Behring, Marburg, Germany) and Tetanus toxid (1 mg/ml, Sigma) before radioactive label. CPM values representing wells containing no antigen were subtracted from the data shown.
